<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02777151</url>
  </required_header>
  <id_info>
    <org_study_id>R3470-3471-3479-HV-1528</org_study_id>
    <nct_id>NCT02777151</nct_id>
  </id_info>
  <brief_title>Study of Safety, Tolerability, and Pharmacokinetics of REGN3470-3471-3479 in Healthy Adult Volunteers</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenously Administered REGN3470-3471-3479 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Health and Human Services</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, randomized, double-blind, placebo-controlled, dose escalation study
      evaluating the safety, tolerability, pharmacokinetics (PK) and immunogenicity of
      REGN3470-3471-3479 in healthy adult volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 27, 2016</start_date>
  <completion_date type="Actual">April 26, 2017</completion_date>
  <primary_completion_date type="Actual">April 26, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of TEAEs through the end of the study visit in subjects treated with REGN3470-3471-3479 in a fixed dose combination</measure>
    <time_frame>From baseline up to day 169</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of REGN3479 in serum over time</measure>
    <time_frame>From baseline up to day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of REGN3471 in serum over time</measure>
    <time_frame>From baseline up to day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of REGN3470 in serum over time</measure>
    <time_frame>From baseline up to day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The presence or absence of antibodies against REGN3470 over time</measure>
    <time_frame>From baseline up to day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The presence or absence of antibodies against REGN3471 over time</measure>
    <time_frame>From baseline up to day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The presence or absence of antibodies against REGN3479 over time</measure>
    <time_frame>From baseline up to day 169</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>REGN3470-3471-3479 dosing level 1 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>REGN3470-3471-3479 dosing level 2 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>REGN3470-3471-3479 dosing level 3 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>REGN3470-3471-3479 dosing level 4 or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN3470-3471-3479</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy man or woman between the ages of 18 and 60

          2. Body mass index (BMI) between 18 and 30 kg/m2, inclusive

          3. Willing and able to comply with clinic visits and study-related procedures

          4. Provide signed informed consent

          5. Able to understand and complete study-related questionnaires

        Exclusion Criteria:

          1. Use of any medications started within 30 days prior to the screening visit including,
             prescription medications, nutritional supplements, and over-the-counter medications
             except for vitamin supplements, and recommended doses of acetaminophen, aspirin or
             ibuprofen

          2. Hospitalization for any reason within 60 days prior to the screening visit

          3. History of or positive human immunodeficiency virus (HIV) screen result at the
             screening visit

          4. History of or positive blood test for hepatitis B surface antigen (HBsAg) or hepatitis
             B core antibody (HBcAb) or hepatitis C virus (HCV) antibody at the screening visit

          5. History of drug or alcohol abuse within 1 year prior to screening

          6. Participation in any clinical research study evaluating another investigational drug
             or therapy within 30 days or at least 5 half-lives (whichever is longer), of the
             investigational drug prior to the screening visit

          7. Any history of receiving treatment, vaccine or mAbs against the Ebola virus

          8. Pregnant or breast-feeding women

          9. Sexually active men* or women of childbearing potential** who are unwilling to
             practice adequate contraception during the study (adequate contraceptive measures
             include stable use of oral contraceptives or other prescription pharmaceutical
             contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device
             [IUD]; bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or
             jelly, or diaphragm plus contraceptive sponge, foam, or jelly).

               -  Contraception is not required for men with documented vasectomy.

               -  Postmenopausal women must be amenorrheic for at least 12 months in order not to
                  be considered of childbearing potential. A baseline follicle-stimulating hormone
                  (FSH) test will be performed for confirmation of menopausal status. Pregnancy
                  testing and contraception are not required for women with documented hysterectomy
                  or tubal ligation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2016</study_first_submitted>
  <study_first_submitted_qc>May 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2016</study_first_posted>
  <last_update_submitted>February 1, 2018</last_update_submitted>
  <last_update_submitted_qc>February 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

